Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
Where in Hollandia
- Amsterdam · Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingBefejeződött
The registry text, word for word
99mTc-nanocolloid, the world wide used hybrid tracer for dynamic sentinel node biopsy, has recently been replaced with 99mTc-nanoscan. The hybrid form (ICG-99mTc-nanoscan) has not yet been validated, to show the similarity between the lymphatic drainage pattern between ICG-99mTc-nanoscan and 99mTc-nanoscan.
Inclusion: Patient who will undergo a sentinel node procedure in routine care; Patients > 18 years; Patients presenting with:; a primary cutaneous melanoma of head/neck or upper part of the trunk or extremities; OR patients presenting with a primary oral cavity malignancy T1-2N0; OR patients with primary penile cancer; Patients with clinical N0 stage; Patients scheduled for a sentinel node biopsy prior to (re-)excision of the primary lesion; Patients in which ICG-99mTc-nanoscan would be used in routine care or a research setting.
Exclusion: Patients with known allergy to patent blue dye or nanocolloid; History of iodine allergy; Kidney insufficiency; History of hypersensitivity reactions to products containing human serum albumin; Patients who are pregnant or breast-feeding mothers; Hyperthyroid or thyroidal adenoma; Incapacity or unwillingness of participant to give written informed consent.